# Tesamorelin Dosage in the Research: The 2 mg/Day Regimen and Half-Life > Tesamorelin was studied at 2 mg subcutaneously once daily across the pivotal trials, with a 1 mg arm in some studies. Doses, route, half-life, and stability from the literature — research context, not advice. What was administered, to whom, by which route, and for how long — the research record on dose, half-life, and stability. No human dosing instructions. ## The short version Across the studies, tesamorelin was given as a 2 mg shot under the skin once a day — that single regimen carried almost all of the evidence, including FDA approval [1][7]. A few studies tested a smaller 1 mg dose. The peptide clears the blood fast (within roughly half an hour), but the growth-hormone signal it sets off lasts long enough that once a day was enough [16]. This page describes what researchers measured in their trials. It is not a dosing guide, and tesamorelin dosage outside the approved HIV use has not been established in large studies. ## Doses studied in the tesamorelin trials The dominant regimen across the entire literature is 2 mg subcutaneously once daily. It was the dose used in both pivotal Phase 3 trials and is the FDA-approved regimen [1][2]. The 412-patient NEJM trial, the 52-week program, the pooled 806-patient analysis, and the JAMA hepatic-fat trial all administered 2 mg/day [1][2][7][3]. That consistency is part of why the dose is well characterized: nearly every efficacy and safety figure summarized on this site comes from the same 2 mg once-daily exposure, which makes the results directly comparable across studies. A 1 mg subcutaneous once-daily arm has appeared in narrower studies — including a cognition trial in older adults and as a lower arm in a type-2-diabetes safety trial — but the extensively characterized paradigm is the once-daily 2 mg dose [4]. A later, higher-concentration once-daily reformulation also exists; the 2 mg once-daily paradigm remains the one supported by the bulk of the trial evidence. No trial in the corpus tested a substantially higher dose in pursuit of a larger effect, so the dose-response curve above 2 mg is not characterized in the published record. ## Duration and the populations studied Treatment duration in the registration program ran to 26 weeks for the primary visceral-fat endpoint, extended to 52 weeks in the long-term phase [1][2]. The JAMA hepatic-fat trial ran for 6 months [3], the healthy-men mechanistic study for 2 weeks [4], and the 2026 meta-analysis pooled five RCTs of varying length [13]. Across these durations the visceral-fat effect appeared by the 26-week assessment and held through a year of continued dosing [2]. The population matters as much as the schedule. Every pivotal efficacy trial enrolled HIV-positive adults on antiretroviral therapy with abdominal fat accumulation [1][2][7]; the only non-HIV human exposures in the corpus are the mechanistic healthy-men study [4] and a cognition trial in older adults. Read that way, the dose record is a record of what was given to a specific patient group — not a general-population dosing guide. ## Route studied Only one route appears in the clinical record: subcutaneous injection at an abdominal site [1]. It is the only route studied in the trials and the only FDA-approved route. There is no published clinical evidence for oral, intranasal, or other delivery of tesamorelin — the molecule is a 5,135.9-Da peptide, and oral peptides of that size are not absorbed intact, which is consistent with the injectable-only record. The abdominal subcutaneous site is also where the visceral-fat endpoint was measured, though the injection's effect is systemic rather than local: the drug acts on the pituitary, not on the fat beneath the needle [4]. ## Half-life and the sustained IGF-1 effect Population pharmacokinetic modeling reported an apparent plasma clearance of approximately 1,060 L/h, with no clinically relevant demographic covariates and a roughly 13% increase in absorbed fraction by day 14 versus day 1 [16]. Secondary sources (the FDA label and Mayo Clinic) describe a terminal half-life on the order of 26 to 38 minutes. The pharmacology that matters is the gap between molecule and effect. The peptide clears in minutes, but the IGF-1 elevation it triggers persists across a once-daily dosing interval — the basis for the once-daily schedule used in every trial [16]. This is why a fast-clearing peptide can still drive a sustained, day-long hormonal signal. ## Stability and formulation notes The trans-3-hexenoic acid N-terminal modification is what gives the molecule its usable shelf life in the body: it blocks the DPP-IV cleavage that inactivates native GHRH within minutes [8]. Pharmaceutically, tesamorelin is supplied as a lyophilized (freeze-dried) powder that requires reconstitution before injection; the FDA label specifies refrigerated storage and use of the reconstituted solution within a defined window. Research-grade material sold for laboratory use lacks the purity and potency oversight of the approved product, a point flagged across recent peptide reviews [15]. --- Tesamorelin read down to its numbers — one GHRH(1-44) analogue, the visceral-fat and IGF-1 figures left standing alone against the studies that measured them, and the approved-for-HIV-lipodystrophy line drawn exactly where the off-label field begins; an editorial reference plate, not a clinic, a vendor, or a prescription.